MADISON, Wis., Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present late-breaking ...
Data demonstrate long-term impact of the Cologuard test, a powerful tool for preventing and detecting cancer The data assessed the far-reaching benefits of the first and only multi-target stool DNA ...
Note: specificity including non-advanced findings includes colonoscopy results that were negative for cancer or advanced precancer upon histopathological review; specificity including no findings ...
Kam knew it was important to get screened for colon cancer as soon as she was eligible. With her dad’s side of the family being affected by breast, kidney and prostate cancer, Kam wanted to “get all ...
American College of Gastroenterology (ACG) gives BLUE-C study late breaker status at 2023 annual meeting with presentation of the only head-to-head study results versus FIT at ACG High specificity for ...
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the U.S. Food and Drug Administration (FDA) approved ...
With March serving as National Colorectal Cancer Awareness Month, there’s no better way to play a role than by simply to help raise awareness. That’s the mission this week’s Cologuard Classic by Exact ...
Anne grew up in a small farm town in southeast Nebraska, where her upbringing was filled with lessons on problem solving, teamwork and the importance of giving back. These qualities have carried her ...
MADISON, Wis., Oct. 22, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced late-breaking data from the pivotal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback